Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial | BMC Cancer | Full Text

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial | BMC Cancer | Full Text

© haydenbird/iStock

Featured article: SABR-COMET-10: Study protocol for a randomized Phase III Trial

Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. David Palma, Robert Olson and colleagues recently found that SABR was associated with benefits in progression-free survival and overall survival in the Phase II Trial. The goal of this international, Phase III Trial is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions.